newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat VISTAS Phase 2b study met primary endpoint - Brelovitug Phase 2b portion of AZURE-1